Last reviewed · How we verify
IV trivalent saccharose hydroxide ferrous
IV trivalent saccharose hydroxide ferrous, marketed by Fundación Canaria Rafael Clavijo para la Investigación Biomédica, holds a niche position in the pharmaceutical market. The drug's key composition patent is set to expire in 2028, providing a period of exclusivity that supports its market presence. However, the lack of disclosed primary indication and revenue data poses a significant risk in assessing its commercial viability and competitive landscape.
At a glance
| Generic name | IV trivalent saccharose hydroxide ferrous |
|---|---|
| Also known as | Venofer |
| Sponsor | Fundación Canaria Rafael Clavijo para la Investigación Biomédica |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: